StockData
Organon & Co. logo

Organon & Co. (OGN) revenue by segment

OGNNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 8/304% below fair value
$13.92+0.02 (+0.14%)

Close on Nov 18, 2026Market cap $3.66BP/E 18.1Yield 2.44%

Doanh thu theo bộ phận của Organon & Co.

Theo bộ phận kinh doanh

Theo sản phẩm hoặc dịch vụ

Doanh thuFY2025FY2024FY2023FY2022FY2021FY2020FY2019% doanh thuYoY
Nexplanon/Implanon NXT$921.00M$963.00M$830.00M$834.00M$769.00M$680.00M$787.00M14.8%-4.4%
Zetia$342.00M$317.00M$322.00M$370.00M$378.00M$482.00M$590.00M5.5%+7.9%
Other$338.00M$328.00M$319.00M$326.00M$200.00M$107.00M$238.00M5.4%+3.0%
Atozet$324.00M$473.00M$519.00M$457.00M$458.00M$453.00M$391.00M5.2%-31.5%
Other Non-Opiod Pain, Bone and Dermatology$301.00M$295.00M$275.00M$273.00M$286.00M$278.00M$214.00M4.8%+2.0%
Arcoxia$265.00M$270.00M$257.00M$241.00M$244.00M$258.00M$288.00M4.3%-1.9%
Follistim AQ$264.00M$237.00M$262.00M$229.00M$237.00M$193.00M$241.00M4.2%+11.4%
Nasonex$262.00M$276.00M$266.00M$260.00M$206.00M$218.00M$293.00M4.2%-5.1%
Singulair$252.00M$359.00M$404.00M$411.00M$413.00M$462.00M$698.00M4.1%-29.8%
Renflexis$251.00M$274.00M$278.00M$226.00M$186.00M$135.00M$96.00M4.0%-8.4%
Hadlima$228.00M$142.00M$44.00M$19.00M$13.00M$0–3.7%+60.6%
Cozaar/Hyzaar$219.00M$243.00M$281.00M$323.00M$357.00M$386.00M$442.00M3.5%-9.9%
Other Women's Health$174.00M$158.00M$147.00M$138.00M$206.00M$270.00M$173.00M2.8%+10.1%
Emgality$174.00M$107.00M$0$0–––2.8%+62.6%
Dulera$153.00M$203.00M$194.00M$180.00M$190.00M$222.00M$217.00M2.5%-24.6%
Diprospan$150.00M$139.00M$91.00M$122.00M$125.00M$118.00M$102.00M2.4%+7.9%
Fosamax$143.00M$151.00M$159.00M$152.00M$175.00M$180.00M$197.00M2.3%-5.3%
Vtama$128.00M$12.00M$0$0–––2.1%+966.7%
Marvelon/Mercilon$127.00M$134.00M$134.00M$110.00M$98.00M$95.00M–2.0%-5.2%
Other Cardiovascular$126.00M$133.00M$139.00M$146.00M$191.00M$239.00M$134.00M2.0%-5.3%
Clarinex$123.00M$127.00M$136.00M$125.00M$111.00M$130.00M$142.00M2.0%-3.1%
Propecia$118.00M$111.00M$125.00M$125.00M$136.00M$129.00M$131.00M1.9%+6.3%
Ganirelix Acetate Injection$101.00M$109.00M$110.00M$123.00M$111.00M$81.00M$112.00M1.6%-7.3%
Vytorin$100.00M$108.00M$129.00M$130.00M$164.00M$182.00M$285.00M1.6%-7.4%
Ontruzant$99.00M$141.00M$155.00M$122.00M$126.00M$115.00M$83.00M1.6%-29.8%
Proscar$97.00M$95.00M$97.00M$101.00M$117.00M$176.00M$203.00M1.6%+2.1%
Nuva Ring$91.00M$115.00M$176.00M$219.00M$191.00M$236.00M$879.00M1.5%-20.9%
Brenzys$80.00M$77.00M$73.00M$75.00M$63.00M$74.00M$72.00M1.3%+3.9%
Jada$74.00M$61.00M$43.00M$20.00M$3.00M––1.2%+21.3%
Other Respiratory$52.00M$53.00M$64.00M$61.00M$89.00M$118.00M$25.00M0.8%-1.9%
Other Biosimilars$33.00M$28.00M$43.00M–$49.00M$6.00M$00.5%+17.9%
Rosuzet$24.00M$49.00M$70.00M$71.00M$68.00M$130.00M$120.00M0.4%-51.0%
Aybintio–$28.00M$43.00M$39.00M$36.00M$6.00M–––
Emgality/Rayvow–$107.00M$0$0–––––
Other Non-Opioid Pain, Bone and Dermatology–$295.00M$275.00M$273.00M–––––
Cerazette––––$70.00M$67.00M$71.00M––
Asmanex––––$63.00M$83.00M$94.00M––
Diprosone––––$87.00M$83.00M$84.00M––
Sinemet––––$71.00M$77.00M$79.00M––
Remeron––––$66.00M$64.00M$82.00M––
Zocor––––$65.00M$77.00M$112.00M––

Theo khu vực

Doanh thuFY2025FY2024FY2023FY2022FY2021FY2020FY2019% doanh thuYoY
Intl$4.61B$4.83B$4.79B$4.74B$4.92B$5.12B$5.76B74.2%-4.5%
Europe and Canada$1.62B$1.76B$1.67B$1.63B$1.74B$1.73B$1.89B26.0%-8.2%
United States$1.60B$1.57B$1.48B$1.44B$1.38B$1.41B$2.02B25.8%+2.0%
Latin America, Middle East, Russia, and Africa$1.07B$1.03B$965.00M$895.00M$841.00M$857.00M$923.00M17.2%+3.7%
Asia Pacific and Japan$1.00B$1.05B$1.13B$1.14B$1.17B$1.54B$1.79B16.1%-4.8%
China$829.00M$847.00M$864.00M$917.00M$933.00M$873.00M$1.03B13.3%-2.1%
Other$93.00M$137.00M$154.00M$151.00M$233.00M$133.00M$124.00M1.5%-32.1%

Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của Organon (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của Organon, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.

Chỉ số vận hành

Manufacturing facilitiesFY2025FY2024FY2023FY2022FY2021YoY
Manufacturing facilities666660.0%

Các số lượng và quy mô Organon gắn thẻ trong thuyết minh hồ sơ 10-K, 10-Q (XBRL), tính đến cuối mỗi kỳ. Phần phân tách giữ theo cách công ty tự đặt tên; mỗi chỉ số hiện tối đa 15 dòng.

See a number that looks wrong?